Cerise Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 02-12-2024
- Paid Up Capital ₹ 0.20 M
as on 02-12-2024
- Company Age 9 Year, 11 Months
- Last Filing with ROC 31 Mar 2018
- Revenue %
(FY 2017)
- Profit -1.06%
(FY 2017)
- Ebitda -3.36%
(FY 2017)
- Net Worth -16.27%
(FY 2017)
- Total Assets -15.11%
(FY 2017)
About Cerise Pharmaceuticals
The Corporate was formerly known as Berry Pharmaceuticals Private Limited. The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2018. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M, as per Ministry of Corporate Affairs (MCA) records.
Satya Pandey and Shailesh Pandey serve as directors at the Company.
- CIN/LLPIN
U24132MH2014PTC260450
- Company No.
260450
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Dec 2014
- Date of AGM
30 Sep 2018
- Date of Balance Sheet
31 Mar 2018
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Cerise Pharmaceuticals Private Limited offer?
Cerise Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Common Disease Medicines, Pharmaceutical Tablets, Nutraceuticals & Dietary Supplements, Dietary Supplements, Vitamin Tablets & Capsules, Skin Ointment, Pain Relief Drugs & Pharmaceuticals, Diclofenac.
Who are the key members and board of directors at Cerise Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satya Pandey  | Director | 29-Dec-2014 | Current |
| Shailesh Pandey | Director | 29-Dec-2014 | Current |
Financial Performance of Cerise Pharmaceuticals.
Cerise Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 1.06% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cerise Pharmaceuticals?
In 2017, Cerise Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cerise Pharmaceuticals?
Unlock and access historical data on people associated with Cerise Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cerise Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cerise Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
